Oropouche in pregnancy tripled adverse maternal outcomes in Rio cohort

The clearest evidence yet that Oropouche virus harms pregnancies comes from a prospective cohort study of 544 pregnant women in Rio de Janeiro state, Brazil, published online ahead of print in The Lancet Infectious Diseases on 19 October 2026 [s1]. The study is the first to compare adverse maternal and infant outcomes after Oropouche infection against outcomes in uninfected pregnancies from the same high-transmission areas, rather than describing infected cases alone [s1].

What the cohort found

Researchers enrolled women receiving prenatal care in municipalities with, or at high risk of, Oropouche outbreaks, following them between 29 November 2024 and 8 October 2025 [s1]. Maternal blood, urine and saliva were tested by RT-PCR at enrolment and at pregnancy endpoints, alongside IgG and IgM serology, placental tissue PCR and immunohistochemistry [s1]. A confirmed infection required a positive PCR in blood, urine, saliva or placenta, positive placental immunohistochemistry, or IgM or IgG seroconversion; a single positive IgM without PCR counted only as a possible infection [s1].

Of the 544 participants, 130 (24%) had confirmed Oropouche infection, 143 (26%) had possible infection, and 271 (50%) had no infection [s1]. The median RT-PCR cycle threshold was 29.7 (IQR 25.8-34.9), and 104 of the 130 confirmed cases (80%) went on to develop detectable IgG antibodies [s1]. Symptoms were recorded in 80 (62%) of the confirmed infections, but symptoms themselves were not necessarily tied to worse outcomes (adjusted relative risk 0.84, 95% credible interval 0.51-1.21) [s1].

The outcome gap

By the end of follow-up, 119 confirmed-infection pregnancies and 193 uninfected pregnancies had reached an endpoint of livebirth, stillbirth or miscarriage [s1]. Livebirths occurred in 105 (88%) of the confirmed group against 187 (97%) of the uninfected group [s1].

The authors defined adverse maternal outcomes as maternal death or disability, fetal loss, or haemorrhage, and adverse infant outcomes as neonatal death or malformations [s1]. Adverse maternal outcomes occurred in 21 (18%) of women with confirmed infection versus 14 (7%) of women with no infection — an adjusted relative risk of 2.90 (95% credible interval 1.52-5.35) after accounting for maternal age, other congenital infections, and tobacco, alcohol and drug use in pregnancy [s1]. Within that, the risk of fetal loss was more than three times higher in confirmed infections (adjusted relative risk 3.08, 1.28-7.29), and the risk of haemorrhage close to three times higher (2.79, 1.22-6.21) [s1].

The infant signal was starker still. The adjusted relative risk for adverse infant outcomes was 9.18 (95% credible interval 1.89-47.88) [s1]. Central nervous system abnormalities were found in eight (8%) infants born to mothers with confirmed infection and in none of the infants born to uninfected mothers [s1]. The study's authors concluded that Oropouche infection during pregnancy is associated with severe maternal and infant outcomes, including maternal haemorrhage, fetal loss and infant CNS abnormalities [s1].

Why it matters now

Oropouche virus is a midge- and mosquito-borne arbovirus long endemic to the Amazon basin, but its range and case counts have expanded sharply across South America and the Caribbean since 2024, raising questions about whether it behaves like Zika in pregnancy. Until now, the signal of congenital harm rested largely on case reports and laboratory findings rather than a comparison group. By following exposed and unexposed pregnancies side by side in the same outbreak setting, this cohort moves the question from anecdote toward quantified risk — and the direction of that risk is unfavourable across maternal haemorrhage, fetal loss and neurological abnormality in the newborn [s1].

The numbers carry the usual caveats of an observational study. The confidence interval around the nine-fold infant-outcome estimate is extremely wide (1.89-47.88), reflecting how few adverse infant events were observed, so the precise magnitude is uncertain even though the lower bound still excludes no effect [s1]. Infections were classified using a layered PCR-and-serology definition, and the cohort was drawn from areas already selected for high transmission [s1]. What the study establishes is not a firm effect size but a consistent and biologically coherent pattern: across maternal and infant endpoints alike, confirmed Oropouche infection tracked with more harm than its absence [s1].

For antenatal services in outbreak zones, the practical implication is that Oropouche can no longer be treated as a self-limiting febrile illness of pregnancy. The work was funded by Brazilian research agencies including FAPERJ, CNPq, the Ministry of Health and Fiocruz, together with the European Health and Digital Executive Agency [s1].

This article is informational and is not medical advice.